AXIOS January 26, 2022
Antiviral COVID treatments are hailed as a pandemic game-changer, but they’re currently in very short supply — and that’s only one of several barriers to access for high-risk patients.
The big picture: Even when supply ramps up, it will still be tricky to connect some of the most vulnerable patients to the pills without changes to the process.
Why it matters: Recently approved antivirals reduce the risk of hospitalization and death by up to 89%.
- But patients have a relatively short window of time to begin the treatment regimen once they’re diagnosed, meaning that access to timely testing, a provider who can write a prescription, and the pills themselves are all critical.
Between the lines: These three distinct...
Today's Sponsors
Today's Sponsor